SCN9A and cancer: By simultaneously inhibiting Nav1.7 and NCX1, this strategy not only alleviates pain hypersensitivity but also more effectively suppresses neuroinflammatory signaling, providing a promising therapeutic intervention for refractory cancer‐induced bone pain.